Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Dezembro 2024 - 9:30AM
Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has
granted equity awards to new non-executive employees who joined the
Company. The equity awards were approved in accordance with Nasdaq
Listing Rule 5635(c)(4).
On November 30, 2024, the Compensation Committee
of Abeona’s Board of Directors granted restricted stock equity
awards as a material inducement to employment to nine individuals
hired by Abeona, which equity awards relate to, in the aggregate,
up to 44,700 restricted shares of Abeona common stock. One-third of
the shares subject to such restricted stock awards will vest yearly
on each anniversary of the Grant Date, such that the shares subject
to such restricted stock awards granted to each employee will be
fully vested on the third anniversary of the Grant Date, in each
case, subject to each employee’s continued employment with Abeona
on the applicable vesting dates.
About Abeona Therapeutics
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical
company developing cell and gene therapies for serious diseases.
Prademagene zamikeracel (pz-cel) is Abeona’s investigational
autologous, COL7A1 gene-corrected epidermal sheets currently in
development for recessive dystrophic epidermolysis bullosa. The
Company’s fully integrated cell and gene therapy cGMP manufacturing
facility served as the manufacturing site for pz-cel used in its
Phase 3 VIITAL™ trial, and is capable of supporting commercial
production of pz-cel upon FDA approval. The Company’s development
portfolio also features AAV-based gene therapies for ophthalmic
diseases with high unmet medical need. Abeona’s novel,
next-generation AAV capsids are being evaluated to improve tropism
profiles for a variety of devastating diseases. For more
information, visit www.abeonatherapeutics.com.
Forward-Looking Statements This
press release contains certain statements that are forward-looking
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, and that involve risks and uncertainties. We have
attempted to identify forward-looking statements by such
terminology as “may,” “will,” “believe,” “anticipate,” “expect,”
“intend,” “potential,” and similar words and expressions (as well
as other words or expressions referencing future events, conditions
or circumstances), which constitute and are intended to identify
forward-looking statements. Actual results may differ materially
from those indicated by such forward-looking statements as a result
of various important factors, numerous risks and uncertainties,
including but not limited to, the timing and outcome of the FDA’s
review of our BLA resubmission for pz-cel; the FDA’s grant of a
Priority Review Voucher upon pz-cel approval; continued interest in
our rare disease portfolio; our ability to enroll patients in
clinical trials; the outcome of future meetings with the FDA or
other regulatory agencies, including those relating to preclinical
programs; the ability to achieve or obtain necessary regulatory
approvals; the impact of any changes in the financial markets and
global economic conditions; risks associated with data analysis and
reporting; and other risks disclosed in the Company’s most recent
Annual Report on Form 10-K and subsequent periodic reports filed
with the Securities and Exchange Commission. The Company undertakes
no obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of
this press release, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Investor and Media Contact:
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com
Abeona Therapeutics (NASDAQ:ABEO)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Abeona Therapeutics (NASDAQ:ABEO)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024